NAMS · ISSUER CIK 1936258
NewAmsterdam Pharma Co N.V.
Between Aug 1, 2026 and Oct 29, 2026, 4 NewAmsterdam Pharma Co N.V. insiders reported $227K of open-market purchases and $4.7M of sales on SEC Form 4. The largest buyer was Davidson Michael H. (Chief Executive Officer, Director), with $227K.
↗4 insiders filed
Original Form 4 filings from Aug 1, 2026 to Oct 29, 2026. 2 of 3 sales were reported under a 10b5-1 plan.
$227KInsider buying
$4.7MInsider selling
−$4.4MNet open-market
Oct 2, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 2, 202616:30 | Sep 30, 2026 | NAMS | Chief Scientific Officer, Director | S · Sell10b5-1 | $25.03 | −50,246 | 69,302 | -42% | −$1.3M | ||
| Oct 2, 202616:30 | Sep 30, 2026 | NAMS | Chief Scientific Officer, Director | M · Exercise10b5-1 | — | +50,246 | 119,548 | +73% | — | ||
| Sep 15, 202616:30 | Sep 14, 2026 | NAMS | Chief Executive Officer, Director | P · Buy | $22.65 | +10,000 | 792,923 | +1% | +$227K | -38.8% | -8.3% |
| Sep 9, 202616:30 | Sep 4, 2026 | NAMS | Director | S · SellLate 5d | $25.32 | −1,600 | 8,760 | -15% | −$41K | ||
| Sep 3, 202616:30 | Sep 1, 2026 | NAMS | Vice President, Controller | A · Grant | — | +3,200 | 3,200 | New | — | ||
| Aug 25, 202616:30 | Aug 24, 2026 | NAMS | Chief Scientific Officer, Director | S · Sell10b5-1 | $26.91 | −125,000 | 69,302 | -64% | −$3.4M | ||
| Aug 25, 202616:30 | Aug 24, 2026 | NAMS | Chief Scientific Officer, Director | M · Exercise10b5-1 | — | +125,000 | 194,302 | +180% | — |